Psoriasis-Japan Drug Forecast and Market Analysis to 2024: KenResearch.com

Psoriasis-Japan Drug Forecast and Market Analysis to 2024 Summary Psoriasis (PsO) is an incurable genetic, systemic, inflammatory, and chronic skin disorder with an overall prevalence of 2-3% worldwide. Specifically, adult plaque psoriasis, the most common form of Psoriasis, is the focus of this report. Although not life-threatening, Psoriasis causes tremendous morbidity and personal angst for… Read More »

Psoriasis-US Drug Forecast and Market Analysis to 2024: KenResearch.com

Psoriasis-US Drug Forecast and Market Analysis to 2024 Summary Psoriasis (PsO) is an incurable genetic, systemic, inflammatory, and chronic skin disorder with an overall prevalence of 2-3% worldwide. Specifically, adult plaque psoriasis, the most common form of Psoriasis, is the focus of this report. Although not life-threatening, Psoriasis causes tremendous morbidity and personal angst for… Read More »

Growth Differentiation Factor 8 Myostatin or GDF-8-Pipeline Review, H1 2016: KenResearch.com

Growth/Differentiation Factor 8 (Myostatin or GDF-8)-Pipeline Review, H1 2016 Summary Global Markets Direct’s, ‘Growth/Differentiation Factor 8 (Myostatin or GDF-8)-Pipeline Review, H1 2016’, provides in depth analysis on Growth/Differentiation Factor 8 (Myostatin or GDF-8) targeted pipeline therapeutics. The report provides comprehensive information on the Growth/Differentiation Factor 8 (Myostatin or GDF-8), targeted therapeutics, complete with analysis by… Read More »

CD40 Ligand T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG-Pipeline Review, H1 2016: KenResearch.com

CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG)-Pipeline Review, H1 2016 Summary Global Markets Direct’s, ‘CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG)-Pipeline Review, H1… Read More »

C5a Anaphylatoxin Chemotactic Receptor 1 C5a Anaphylatoxin Chemotactic Receptor or C5a-R or CD88 or C5AR1-Pipeline Review, H1 2016: KenResearch.com

C5a Anaphylatoxin Chemotactic Receptor 1 (C5a Anaphylatoxin Chemotactic Receptor or C5a-R or CD88 or C5AR1)-Pipeline Review, H1 2016 Summary Global Markets Direct’s, ‘C5a Anaphylatoxin Chemotactic Receptor 1 (C5a Anaphylatoxin Chemotactic Receptor or C5a-R or CD88 or C5AR1)-Pipeline Review, H1 2016’, provides in depth analysis on C5a Anaphylatoxin Chemotactic Receptor 1 (C5a Anaphylatoxin Chemotactic Receptor or… Read More »

Apolipoprotein E ApoE-Pipeline Review, H1 2016: KenResearch.com

Apolipoprotein E (ApoE)-Pipeline Review, H1 2016 Summary Global Markets Direct’s, ‘Apolipoprotein E (ApoE)-Pipeline Review, H1 2016’, provides in depth analysis on Apolipoprotein E (ApoE) targeted pipeline therapeutics. The report provides comprehensive information on the Apolipoprotein E (ApoE) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration… Read More »

Catenin Beta-1 Beta Catenin or CTNNB1-Pipeline Review, H1 2016: KenResearch.com

Catenin Beta-1 (Beta Catenin or CTNNB1)-Pipeline Review, H1 2016 Summary Global Markets Direct’s, ‘Catenin Beta-1 (Beta Catenin or CTNNB1)-Pipeline Review, H1 2016’, provides in depth analysis on Catenin Beta-1 (Beta Catenin or CTNNB1) targeted pipeline therapeutics. The report provides comprehensive information on the Catenin Beta-1 (Beta Catenin or CTNNB1), targeted therapeutics, complete with analysis by… Read More »

C-X-C Chemokine Receptor Type 4 Fusin or Leukocyte-Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide-Associated Protein 3 or Stromal Cell-Derived Factor 1 Receptor or CD184 or CXCR4-Pipeline Review, H1 2016: KenResearch.com

C-X-C Chemokine Receptor Type 4 (Fusin or Leukocyte-Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide-Associated Protein 3 or Stromal Cell-Derived Factor 1 Receptor or CD184 or CXCR4)-Pipeline Review, H1 2016 Summary Global Markets Direct’s, ‘C-X-C Chemokine Receptor Type 4 (Fusin or Leukocyte-Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide-Associated Protein 3 or Stromal Cell-Derived Factor 1 Receptor… Read More »

Metabotropic Glutamate Receptor 2 mGluR2 or GRM2 or GPRC1B or MGLUR2-Pipeline Review, H1 2016: KenResearch.com

Metabotropic Glutamate Receptor 2 (mGluR2 or GRM2 or GPRC1B or MGLUR2)-Pipeline Review, H1 2016 Summary Global Markets Direct’s, ‘Metabotropic Glutamate Receptor 2 (mGluR2 or GRM2 or GPRC1B or MGLUR2)-Pipeline Review, H1 2016’, provides in depth analysis on Metabotropic Glutamate Receptor 2 (mGluR2 or GRM2 or GPRC1B or MGLUR2) targeted pipeline therapeutics. The report provides comprehensive… Read More »

Prostaglandin E2 Receptor EP4 Subtype Prostanoid EP4 Receptor or PTGER4-Pipeline Review, H1 2016: KenResearch.com

Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4)-Pipeline Review, H1 2016 Summary Global Markets Direct’s, ‘Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4)-Pipeline Review, H1 2016’, provides in depth analysis on Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) targeted pipeline therapeutics. The report provides comprehensive information on the… Read More »